🇺🇸 FDA
Patent

US 12365728

DLL3 single domain antibodies and therapeutic compositions thereof

granted A61KA61K2039/505A61K2239/55

Quick answer

US patent 12365728 (DLL3 single domain antibodies and therapeutic compositions thereof) held by Inhibrx Biosciences, Inc. expires Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx Biosciences, Inc.
Grant date
Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K2039/505, A61K2239/55, A61K40/11, A61K40/4202